ScreenerHero

FRX Fennec Pharmaceuticals Inc.

TSX · CA · Healthcare · Biotechnology · fennecpharma.com
15.14CAD+4.34%Mkt Cap: 370.56M $P/E: —

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap370.56M USD
Enterprise Value340.52M USD
Revenue (TTM)43.13M USD
Gross Profit29.77M USD
Net Income (TTM)-7.09M USD
Revenue/Share1.85 CAD
Last Price15.14 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA31447P1009
Valuation
P/E (Trailing)—
P/E (Forward)11.01
PEG—
EV/EBITDA-457.81
EV/Revenue7.90
P/S8.59
P/B8.41
EPS (TTM)-0.17
EPS (Forward)1.32
52W Range
7.59075% of range17.64
52W High17.64 CAD
52W Low7.590 CAD
Profitability
Gross Margin91.57%
Oper. Margin9.72%
EBITDA Margin-1.73%
Profit Margin-21.82%
ROE-27.46%
ROA-13.81%
Growth
Revenue Growth85.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.08M USD
CapEx (TTM)—
FCF Margin1.81%
FCF Yield0.21%
Net Debt-30.04M USD
Net Debt/EBITDA40.39
Balance Sheet
Debt/Equity0.00
Current Ratio5.85
Quick Ratio5.21
Book Value/Sh1.73 CAD
Cash/Share1.18 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:3
Split DateSep 5, 2014
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.35.07M
Float19.88M
Insiders14.12%
Institutions54.37%
Short Interest
Short Ratio47.7d
Short % Float0.09%
Short % Out.0.07%
Shares Short26.23K
Short (prev mo.)24.67K
Technical
SMA 5015.74 (-3.8%)
SMA 20012.40 (+22.1%)
Beta1.10
S&P 52W Chg14.58%
Avg Vol (30d)751
Avg Vol (10d)260
Technical Indicators
RSI (14)39.8
MACD-0.2180
MACD Signal-0.0021
MACD Hist.-0.2158
BB Upper18.18 CAD
BB Middle15.97 CAD
BB Lower13.76 CAD
BB Width27.71%
ATR (14)0.4722 CAD
Vol Ratio (20d)0.29x